StockData
Alnylam Pharmaceuticals, Inc. logo

Alnylam Pharmaceuticals, Inc. (ALNY) KPIs and segments

ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3049% below fair value
$149.40−7.10 (-4.54%)

Close on Nov 18, 2026Market cap $20.01BP/E 7.8Yield –

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Alnylam Pharmaceuticals · năm tài chính kết thúc ngày 31 tháng 12

Nhìn nhanh KPI của Alnylam Pharmaceuticals: 50 chỉ số vận hành, trong đó có Total TTR Franchise YoY Revenue Growth at Constant, AMVUTTRA YoY Revenue Growth at Constant Exchange Rate và ONPATTRO YoY Revenue Growth at Constant Exchange Rate, lấy từ 254 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Net product revenues($M)
1,2921,1721,036995851672469451420410365346
AMVUTTRA($M)3
1,1301,012890827685492310287259230195175
United States($M)
909809703642530361198183169148130122
Europe($M)
13111911312111292.980.169.865.156.843.730.3
Rest of World (primarily Japan)($M)
91.083.774.164.043.037.731.933.424.824.921.322.8
Royalty revenue($M)
94.771.749.061.446.240.026.535.423.422.410.617.0
GIVLAARI($M)3
89.589.874.486.873.980.867.064.671.062.158.159.3
United States($M)
57.55849.156.350.455.243.845.040.441.238.739.5
Europe($M)
20.924.320.319.518.721.018.518.016.316.315.316.5
Rest of World (primarily Japan)($M)
11.27.445.0111.04.744.734.631.6014.44.594.013.29
Collaborations($M)
71.547.282.140.935261.599.210757.422711976.4
OXLUMO($M)3
52.552.151.349.652.846.942.143.640.240.642.632.7
Europe($M)
23.222.724.422.822.321.921.018.820.020.521.419.4
United States($M)
18.418.517.017.620.716.014.118.814.915.713.310.6
Rest of World (primarily Japan)($M)
10.910.99.979.249.768.927.005.975.314.367.892.72
ONPATTRO($M)3
19.618.520.531.739.152.549.556.150.377.269.279.0
United States($M)
9.719.8610.212.012.522.115.619.916.222.116.520.5
Rest of World (primarily Japan)($M)
5.133.092.757.706.929.247.388.079.7618.17.9914.0
Europe($M)
4.765.517.5712.019.721.226.528.124.337.144.744.5
Total TTR Franchise YoY Revenue Growth at Constant Exchange Rate (CER)(%)1
60.0%89.0%150.0%149.0%131.0%75.0%38.0%34.0%35.0%39.0%30.0%31.0%
Total TTR Franchise YoY Revenue Growth (As Reported)(%)
59.0%89.0%153.0%151.0%135.0%77.0%36.0%35.0%34.0%37.0%29.0%33.0%
AMVUTTRA (vutrisiran) YoY Revenue Growth at Constant Exchange Rate (CER)(%)4
66.0%106.0%183.0%187.0%162.0%112.0%75.0%77.0%101,768.0%
AMVUTTRA Worldwide YoY Revenue Growth (As Reported)(%)
65.0%106.0%187.0%189.0%165.0%114.0%59.0%74.0%74.0%195,241.0%
AMVUTTRA — United States YoY Revenue Growth (As Reported)(%)
71.0%124.0%255.0%214.0%143.0%52.0%49.0%54.0%65.0%
AMVUTTRA — Europe YoY Revenue Growth (As Reported)(%)
17.0%28.0%41.0%72.0%64.0%83.0%235.0%294.0%
AMVUTTRA — Rest of World YoY Revenue Growth (As Reported)(%)
112.0%122.0%132.0%73.0%52.0%50.0%57.0%17.0%33.0%
ONPATTRO (patisiran) YoY Revenue Growth at Constant Exchange Rate (CER)(%)4
-50.0%-65.0%-61.0%-45.0%-25.0%-33.0%-38.0%-15.0%102,493.0%
ONPATTRO Worldwide YoY Revenue Growth (As Reported)(%)
-50.0%-65.0%-59.0%-44.0%-22.0%-32.0%-29.0%-38.0%-16.0%69,217.0%
ONPATTRO — United States YoY Revenue Growth (As Reported)(%)
-22.0%-55.0%-35.0%-23.0%0.0%-6.0%-26.0%-13.0%-45.0%
ONPATTRO — Europe YoY Revenue Growth (As Reported)(%)
-76.0%-74.0%-71.0%-19.0%-43.0%-41.0%-52.0%-34.0%-25.0%
ONPATTRO — Rest of World YoY Revenue Growth (As Reported)(%)
-26.0%-67.0%-63.0%-29.0%-49.0%-8.0%4.0%90.0%-39.0%
Total TTR Franchise Net Product Revenues (AMVUTTRA + ONPATTRO)($M)
1,1501,030910858724545360343309307265
Total Rare Franchise YoY Revenue Growth at Constant Exchange Rate (CER)(%)1
13.0%10.0%10.0%23.0%11.0%23.0%11.0%17.0%82,884.0%82,111.0%72,067.0%
Total Rare Franchise YoY Revenue Growth (As Reported)(%)
12.0%11.0%15.0%26.0%14.0%24.0%8.0%18.0%111,263.0%102,735.0%100,705.0%
GIVLAARI (givosiran) YoY Revenue Growth at Constant Exchange Rate (CER)(%)4
22.0%10.0%7.0%32.0%2.0%29.0%31.0%8.0%21.0%24.0%
GIVLAARI Worldwide YoY Revenue Growth (As Reported)(%)
21.0%11.0%11.0%34.0%4.0%30.0%15.0%31.0%7.0%21.0%26.0%
GIVLAARI — United States YoY Revenue Growth (As Reported)(%)
14.0%5.0%12.0%25.0%34.0%13.0%9.0%17.0%28.0%
GIVLAARI — Europe YoY Revenue Growth (As Reported)(%)
12.0%16.0%9.0%15.0%29.0%21.0%31.0%16.0%6.0%
GIVLAARI — Rest of World YoY Revenue Growth (As Reported)(%)
135.0%57.0%8.0%-67.0%3.0%15.0%206.0%-47.0%28.0%
OXLUMO (lumasiran) YoY Revenue Growth at Constant Exchange Rate (CER)(%)4
0.0%9.0%13.0%10.0%27.0%13.0%40.0%68.0%75.0%32.0%
OXLUMO Worldwide YoY Revenue Growth (As Reported)(%)
-1.0%11.0%22.0%14.0%31.0%15.0%-1.0%40.0%68.0%77.0%37.0%
OXLUMO — United States YoY Revenue Growth (As Reported)(%)
-11.0%16.0%20.0%39.0%2.0%6.0%54.0%79.0%47.0%
OXLUMO — Europe YoY Revenue Growth (As Reported)(%)
4.0%3.0%16.0%12.0%7.0%-2.0%32.0%68.0%61.0%
OXLUMO — Rest of World YoY Revenue Growth (As Reported)(%)
11.0%22.0%42.0%84.0%105.0%-11.0%35.0%36.0%340.0%
Total Rare Franchise Net Product Revenues (GIVLAARI + OXLUMO)($M)
142142126136127128109108111103101
Combined Net Product Revenues YoY Growth at Constant Exchange Rate (CER)(%)4
53.0%74.0%117.0%119.0%99.0%62.0%30.0%29.0%35.0%35.0%32.0%30.0%
Combined Net Product Revenues YoY Growth (As Reported)(%)
52.0%74.0%121.0%121.0%103.0%64.0%28.0%30.0%34.0%34.0%32.0%32.0%
Total Consolidated Revenues YoY Growth at Constant Exchange Rate (CER)(%)
17.0%67.0%93.0%83.0%147.0%16.0%22.0%34.0%55.0%29.0%
Total Consolidated Revenues YoY Growth (As Reported)(%)
17.0%67.0%96.0%85.0%149.0%17.0%20.0%35.0%-33.0%107.0%55.0%31.0%
Cost of Goods Sold as % of Net Product Revenues(%)
28.0%25.4%20.0%26.9%23.2%21.1%15.0%22.8%19.5%16.4%15.0%20.8%
Full-Year Guidance — Combined Net Product Revenue Growth at CER (Upper Bound)(%)3
70.0%70.0%77.0%77.0%84.0%68.0%39.0%21.0%
Full-Year Guidance — Combined Net Product Revenue Growth at CER (Lower Bound)(%)
57.0%57.0%64.0%64.0%78.0%59.0%26.0%13.0%
Full-Year Guidance — Combined Net Product Revenue Growth As Reported (Upper Bound)(%)
71.0%71.0%77.0%77.0%85.0%70.0%37.0%33.0%33.0%21.0%21.0%
Full-Year Guidance — Combined Net Product Revenue Growth As Reported (Lower Bound)(%)
57.0%57.0%64.0%64.0%79.0%61.0%25.0%27.0%27.0%13.0%13.0%
Full-Year Guidance — Combined Net Product Revenues (Upper Bound)($M)9
5,1005,1005,3005,3003,0502,8002,2501,6501,6501,5001,500
Full-Year Guidance — Combined Net Product Revenues (Lower Bound)($M)
4,7004,7004,9004,9002,9502,6502,0501,5751,5751,4001,400
Full-Year Guidance — Total TTR Net Product Revenues (Upper Bound)($M)
4,5004,5004,7004,7002,5252,2751,725
Full-Year Guidance — Total TTR Net Product Revenues (Lower Bound)($M)
4,2004,2004,4004,4002,4752,1751,600
Full-Year Guidance — Total Rare Net Product Revenues (Upper Bound)($M)
600600600600525525525
Full-Year Guidance — Total Rare Net Product Revenues (Lower Bound)($M)
500500500500475475450
Full-Year Guidance — Net Revenues from Collaborations & Royalties (Upper Bound)($M)
625625500500750750750650650425425
Full-Year Guidance — Net Revenues from Collaborations & Royalties (Lower Bound)($M)
575575400400650650650575575325325
Full-Year Guidance — Non-GAAP Combined R&D and SG&A Expenses (Upper Bound)($M)
2,8002,8002,8002,8002,2002,2002,2001,8751,8751,7751,775
Full-Year Guidance — Non-GAAP Combined R&D and SG&A Expenses (Lower Bound)($M)
2,7002,7002,7002,7002,1502,1002,1001,7751,7751,6751,675
Combined Net Product Revenues (Worldwide)($M)2
1,2921,1721,036995851672469451420410365346
Total Consolidated Revenues (Product + Collaborations + Royalties)($M)
1,4581,2911,1671,0971,249774594593501660494440
Cost of Goods Sold (GAAP)($M)
36229820826819714270.21038267.354.672
Royalty Revenue YoY Growth (As Reported)(%)1
105.0%79.0%85.0%73.0%98.0%78.0%149.0%136.0%211.0%63.0%
Royalty Revenue YoY Growth at Constant Exchange Rate (CER)(%)
105.0%79.0%85.0%73.0%98.0%78.0%149.0%
Net Revenues from Collaborations YoY Growth (As Reported)(%)5
-80.0%-23.0%-17.0%-62.0%-73.0%-16.0%-87.0%225.0%
Net Revenues from Collaborations YoY Growth at Constant Exchange Rate (CER)(%)
-80.0%-23.0%-17.0%-62.0%-73.0%-16.0%
Regeneron Collaboration Revenue YoY Growth (As Reported)(%)
43.0%-85.0%-9.0%-74.0%-41.0%-84.0%91.0%-53.0%34.0%
Regeneron Collaboration Revenue YoY Growth at Constant Exchange Rate (CER)(%)
43.0%-85.0%-9.0%-74.0%-41.0%-84.0%91.0%
Roche Collaboration Revenue YoY Growth (As Reported)(%)
-88.0%129.0%109.0%174.0%361,927.0%11.0%-77.0%-95.0%91,186.0%
Roche Collaboration Revenue YoY Growth at Constant Exchange Rate (CER)(%)
-88.0%129.0%109.0%174.0%11.0%-77.0%
Remaining Performance Obligations (RPO) — Regeneron Collaboration Transaction Price($M)1
20.928.227.434.134.346.8169167170676335
Remaining Performance Obligations (RPO) — Roche (Zilebesiran) Collaboration Transaction Price($M)
792830870904936870922922922523
Net Revenues from Collaborations (Total)($M)3
71.547.282.14135261.599.210757.422711976.4
Roche Collaboration Revenue — Total (Zilebesiran Cardiovascular Alliance)($M)2
39.141.935.63332718.317.11216.316.572.227.6
Roche — Development Services Revenue($M)
37.640.234.431.325.216.715.810.914.912.87.2023.8
Roche — Other Services & Milestone Revenue($M)
1.601.701.201.601.401.601.201.101.403.70
Regeneron Collaboration Revenue — Total (CNS, Ocular & C5 Programs)($M)4
32.3546.37.8022.532.55130.73820726.827.8
Regeneron — Research & Development Services Revenue($M)
7.30-0.806.600.2012.51313.89.3011.1414.713.5
Regeneron — C5 Cemdisiran License Revenue($M)
0000.300021.519.48.408.801.70-21.1
Regeneron — Manufacturing & Technology Transfer Revenue($M)
0000002.40000
Regeneron — Other Program License Revenue($M)
255.8039.77.301019.613.31.9018.43.10
Other Collaborations Revenue (PeptiDream, Vir Biotechnology & Other)($M)
00.300.100.202.6010.731.14.300.201.102.602.10
Contract Liabilities (Deferred Collaboration Revenue) — Current Balance($M)3
11.743.204.802.5015.128.255.5716976.8103
Contract Liabilities — Collaborations Current($M)
11.743.204.802.5015.128.255.57271.2262291
Contract Liabilities — Regeneron Research Services (Current)($M)
11.743.204.802.5015.127.341.245.541.548.763.4
Collaboration Revenue Recognized from Beginning Contract Liability Balance($M)
4-0.804.800.2012.51328.117.919.520020.4-1.50
Blackstone Sale of Future Royalties (Leqvio) — Effective Interest Rate(%)4
15.0%14.0%11.0%10.0%10.0%10.0%9.0%9.0%9.0%8.0%
Vutrisiran Development Funding Liability — Effective Interest Rate(%)
47.0%51.0%49.0%46.0%
Zilebesiran Development Funding Liability — Effective Interest Rate(%)
31.0%31.0%32.0%32.0%
1.00% Convertible Senior Notes due 2027 — Effective Interest Rate(%)
1.0%1.0%1.0%1.0%1.0%1.0%
0.00% Convertible Senior Notes due 2028 — Effective Interest Rate(%)
1.0%1.0%1.0%1.0%1.0%
Gross-to-Net (GTN) Accrued Rebates, Chargebacks & Discounts — Ending Reserve Balance($M)6
557503477426559474362346
Accrued Government & Managed Care Rebates & Wholesaler Chargebacks — Ending Balance($M)
524473449400537450351326
Accrued Co-Pay Assistance, Prompt-Pay Cash Discounts & Other Incentives — Ending Balance($M)
32.629.627.725.810.920.3
GTN Rollforward — Provisions Recorded for Sales Made in Current Period (Total)($M)2
399346320287244
Provisions for Current Period Sales — Chargebacks & Rebates($M)
366313290257220
Provisions for Current Period Sales — Other Incentives($M)
33.332.630
GTN Rollforward — Provisions (Credits) for Sales Made in Prior Periods (Total)($M)2
3.901.102.105.306.30
Prior Period Adjustments — Chargebacks & Rebates($M)
3.901.101.105.306.30
Prior Period Adjustments — Other Incentives($M)
001
GTN Rollforward — Payments & Credits Issued Relating to Current Period Sales (Total)($M)2
-290-219-161-258-144
Payments/Credits for Current Period Sales — Chargebacks & Rebates($M)
-261-190-147-234-118
Payments/Credits for Current Period Sales — Other Incentives($M)
-29.3-28.2-14.2
GTN Rollforward — Payments & Credits Issued Relating to Prior Period Sales (Total)($M)2
-50.7-100-105-157-8.80
Payments/Credits for Prior Period Sales — Chargebacks & Rebates($M)
-49.8-97.5-92.2-155-8.80
Payments/Credits for Prior Period Sales — Other Incentives($M)
-0.90-2.50-12.9
Inventories by Manufacturing Stage — Total Inventories (Current + Noncurrent)($M)5
11711711611296.6100110115115120126125
Current Inventories, Net($M)
10697.18482.775.471.765.678.576849489.2
Raw Materials($M)
1813.911.714.222.222.923.42422.42625.423.4
Work in Process (siRNA Drug Substance & Bulk Intermediates)($M)
58.85965.565.135.543.8546569.966.576.177
Finished Goods (Labeled Commercial Vials & Syringes)($M)
40.4443932.338.933.83326.423.127.924.825.1
Noncurrent Inventories (Long-Term Pre-Launch & Commercial Stock in Other Assets)($M)
11.319.932.128.921.228.744.836.939.436.432.336.3
Accounts Receivable Disaggregation — Total Accounts Receivable, Net($M)2
1,085913884778965567418405354310321328
Trade Accounts Receivable from Product Sales, Net($M)
906788727670573475312270266249240210
Billed & Unbilled Collaboration Receivables($M)
89.658.710948.834755.680.410364.639.566.399.6
Accrued Expenses — Total Current Balance($M)
1,2361,0969471,0801,154919704794946809699713
GAAP Research & Development Expenses (Total)($M)5
409413365372359324265300271294261272
R&D by Function — Clinical Trial & Outside Manufacturing Services($M)
240244199202171141127129135120126
R&D by Function — Compensation & Related Personnel Benefits($M)
12212512412814614399.212995.113596.4
R&D by Function — Occupancy, Lab Supplies & All Other R&D($M)
47.343.541.442.94239.538.641.740.939.839.1
R&D Costs Incurred Under Regeneron Collaboration($M)
9.8012.21115.914.612.518.910.927.914.318.750.4
R&D Costs Incurred Under Roche (Zilebesiran) Collaboration($M)
66.573.361.254.444.83129.720.627.826.218.144.6
GAAP Selling, General & Administrative Expenses (Total)($M)3
342348323325322323240295221248211198
SG&A by Function — Compensation & Related Personnel Benefits($M)
168167163157189191131160116138117
SG&A by Function — Commercial, Consulting & Professional Services($M)
11912110511388.782.664.782.768.366.756.8
SG&A by Function — Occupancy & All Other SG&A($M)
55.560.654.255.544.749.443.852.3374436.7
Non-GAAP Operating Income (Loss)($M)5
424,916318,066338,790203,350476,19395,48174,789-13,514-31,101137,9021,912-74,410
Non-GAAP Net Income (Loss)($M)
2,241,910251,801273,038169,753396,18044,122-1,2878,048-64,19973,766-20,666-96,643
Non-GAAP Diluted Net Income (Loss) Per Common Share($)
16.261.841.991.252.900.32-0.010.06-0.500.56-0.16-0.77
Non-GAAP Basic Net Income (Loss) Per Common Share($)
16.751.882.051.283.010.34-0.010.06-0.500.58-0.16-0.77
Non-GAAP Research & Development Expenses (Ex-SBC & Milestone Payments)($M)
375,677377,240334,754340,898310,089274,069241,324259,544251,132246,027241,780253,056
Non-GAAP Selling, General & Administrative Expenses (Ex-SBC)($M)
295,743297,191282,509285,062262,590261,186207,035244,319194,983207,224184,665175,214
Blackstone Leqvio Sale of Future Royalties — Noncurrent Liability Carrying Value($M)19
1,5391,5171,4901,4791,4651,4431,4211,4471,4241,4051,3831,377
Blackstone Leqvio Sale of Future Royalties — Current Portion($M)
189167122119112
Blackstone Leqvio Liability — Estimated Fair Value (Level 3)($M)
2,0301,9601,6701,610
Non-Cash Interest Expense on Liability Related to Sale of Future Royalties($M)
57.953.240.537.540.936.53535.330.729.531.627.6
Royalty Payments Remitted to Blackstone on Leqvio Sales($M)
35.326.130.123.218.714.461.712.310.98.1025.75.40
Total Noncurrent Liabilities Related to Sale of Future Royalties & Development Funding($M)
1,4631,4621,4701,4701,334
Total Current Liabilities Related to Sale of Future Royalties & Development Funding($M)
272259228220113
Vutrisiran Development Funding Liability (Blackstone) — Level 3 Balance($M)
170181188194190
Vutrisiran Development Funding Liability — Noncurrent Portion($M)
94.491.289.499.7
Vutrisiran Development Funding Liability — Current Portion($M)
7689.998.594.5
Vutrisiran Development Funding Liability — Fair Value($M)
479555558541
Vutrisiran Development Funding Liability — Interest Expense($M)
21.323.923.9
Vutrisiran Development Funding Liability — Payments Made($M)
-32-30.8-30.1
Zilebesiran Development Funding Liability — Level 3 Balance($M)
25.222.319.617.125.3
Zilebesiran Development Funding Liability — Noncurrent Portion($M)
18.320.212.110.3
Zilebesiran Development Funding Liability — Current Portion($M)
6.902.107.506.80
Zilebesiran Development Funding Liability — Fair Value($M)
120120118116
Zilebesiran Development Funding Liability — New Funding Additions($M)
666
Zilebesiran Development Funding Liability — Interest Expense($M)
2.2021.90
Zilebesiran Development Funding Liability — Payments Made($M)
-5.30-5.30-5.30
1.00% Convertible Senior Notes due 2027 — Estimated Fair Value (Level 2)($M)3
3924344585346531,1101,020
1.00% Convertible Senior Notes due 2027 — Carrying Value($M)
3623613613613941,020
0.00% Convertible Senior Notes due 2028 — Carrying Value($M)
651650649647646
0.00% Convertible Senior Notes due 2028 — Estimated Fair Value (Level 2)($M)
606607615637655
Stock-Based Compensation (SBC) Expense — Total Recognized($M)4
79.186.670.271.610811256.791.645.889.345.442
SBC Expense Allocated to Research & Development($M)
32.935.930.131.348.749.523.840.619.848.119.219.1
SBC Expense Allocated to Selling, General & Administrative($M)
46.350.74040.359.562.132.9512641.226.122.9
SBC Capitalized into Inventory($M)
1.101.101.101.101.101.101.100.800.800.800.800.90
Stock Options Exercised — Total Shares(M)
0.100.180.100.620.560.420.791.260.22
Property, Plant & Equipment (PP&E), Net($M)4
615554518513502500499503507517524526
Operating Lease Right-of-Use (ROU) Assets($M)
178183189195191192197191196198196200
Operating Lease Liabilities — Noncurrent($M)
203211218225223224230230236239238243
Operating Lease Liabilities — Current($M)
46.145.945.745.544.846.14641.942.141.741.741.5
ROU Assets Obtained in Exchange for New Operating Lease Liabilities($M)
0.50008.803.80-1.309.80-0.401.9070.80
Novartis AG (NVS) — Leqvio (inclisiran) Worldwide Net Sales ($M)($M)9
506480452335308298257223198182151123
Novartis AG (NVS) — Leqvio United States Net Sales ($M)($M)
2342141661641461381271161019474
Novartis AG (NVS) — Leqvio Rest of World Net Sales ($M)($M)
272266286171162160130107978877
Novartis AG (NVS) — Leqvio Worldwide Net Sales YoY Growth at Constant Currency (%)(%)
63.0%59.0%69.0%46.0%54.0%61.0%72.0%83.0%119.0%134.0%139.0%190.0%
Novartis AG (NVS) — Leqvio Worldwide Net Sales YoY Growth in USD (%)(%)
64.0%61.0%76.0%50.0%56.0%64.0%70.0%81.0%120.0%133.0%136.0%193.0%
Novartis AG (NVS) — Leqvio United States Net Sales YoY Growth (%)(%)
60.0%55.0%31.0%41.0%45.0%47.0%72.0%68.0%84.0%114.0%100.0%
Novartis AG (NVS) — Leqvio Rest of World Net Sales YoY Growth at Constant Currency (%)(%)
65.0%63.0%106.0%52.0%63.0%74.0%74.0%99.0%177.0%165.0%188.0%
Novartis AG (NVS) — Leqvio Rest of World Net Sales YoY Growth in USD (%)(%)
68.0%66.0%120.0%60.0%67.0%82.0%69.0%98.0%177.0%159.0%185.0%
Novartis AG (NVS) — Leqvio U.S. Months-of-Therapy Equivalent Prescriptions (MOTRx) YoY Growth (%)(%)
60.0%49.0%41.0%56.0%44.0%56.0%70.0%
Novartis AG (NVS) — U.S. Advanced Lipid-Lowering Market MOTRx YoY Growth (%)(%)
46.0%37.0%34.0%35.0%35.0%35.0%37.0%
Sanofi (SNY) — Qfitlia (fitusiran) Worldwide Net Sales (€M)(€M)3
8754410
Sanofi (SNY) — Qfitlia United States Net Sales (€M)(€M)
7754410
Sanofi (SNY) — Qfitlia Europe Net Sales (€M)(€M)
0000000
Sanofi (SNY) — Qfitlia Rest of World Net Sales (€M)(€M)
1000000
Regeneron Pharmaceuticals (REGN) — Direct Clinical R&D Spend on Pozelimab & Cemdisiran (C5 siRNA, $M)($M)
21.423.717.521.616.516.312.830.117.619.81217.6
U.S. Personal Consumption Expenditures: Pharmaceutical & Other Medical Products (FRED: DNRGRC1Q027SBEA, SAAR $B)($M)
3,8593,7903,7003,6673,6153,5303,4653,4183,3583,2883,2443,159
Total Revenues (GAAP)($M)14
1,4581,2911,1671,0971,249774594593501660494440
Cost of Goods Sold & Collaborations (GAAP)($M)
36229820826819714270.21038267.354.672
Research & Development Expenses (GAAP)($M)
409413365372359324265300271294261272
Selling, General & Administrative Expenses (GAAP)($M)
342348323325322323240295221248211198
Total Operating Costs and Expenses (GAAP)($M)
1,1121,060899965881790576698578611538556
Operating Income (Loss) (GAAP)($M)
346231269132368-16.218.1-105-76.948.6-43.4-116
Interest Income($M)
30.928.126.626.628.727.528.73132.129.229.630.4
Interest Expense (Including Non-Cash Royalty Liability Interest)($M)
84.482.169.365.467.561.558.33934.433.335.331.3
Income (Loss) Before Income Taxes($M)
29617822286.3281-41.3-2.40-194-109-11.2-63.6-138
Provision for (Benefit from) Income Taxes($M)
-1,87213.315.7-25.3-12.130.915.9-1102.905.702.300.20
Net Income (Loss) (GAAP)($M)
2,167165206112293-72.2-18.3-83.8-112-16.9-65.9-138
Diluted Earnings (Loss) Per Share (GAAP)($)
15.721.211.512.14-0.55-0.14-0.87-0.13-0.52
Basic Earnings (Loss) Per Share (GAAP)($)
16.191.231.552.23-0.55-0.14-0.87-0.13-0.52
Weighted-Average Diluted Shares Outstanding(M)
138138138137131130129127126
Weighted-Average Basic Shares Outstanding(M)
134134133131131130129127126
Cash, Cash Equivalents and Marketable Securities22
Cash and Cash Equivalents($M)
1,7541,7081,7111,6571,4901,1141,0209691,100969682813
Marketable Debt & Equity Securities($M)
1,8331,6001,2981,2511,2341,7441,6051,7201,6721,6461,6781,616
Accounts Receivable, Net($M)
1,085913884778965567418405354310321328
Inventories (Current)($M)
10697.18482.775.471.765.678.576849489.1
Prepaid Expenses and Other Current Assets($M)
335302242282188147152117145155202126
Total Current Assets($M)
5,1134,6204,2194,0513,9533,6443,2683,2953,3553,1732,9892,983
Property, Plant and Equipment, Net($M)
615554518513502500499503507517524526
Operating Lease Right-of-Use Assets($M)
178183189195191192197191196198196200
Deferred Tax Assets($M)
2,00711411712698.610410711710.1
Other Noncurrent Assets (Including Long-Term Inventory)($M)
60.365.163.659.555.857.273.865.377.671.967.561.9
Total Assets($M)
7,9955,5595,1304,9664,8524,5664,2144,2404,2054,0103,8243,830
Accounts Payable($M)
13510812711611810297.488.470.87478.155.5
Accrued Expenses($M)
1,2361,0969471,0801,154919704794946809699713
Deferred Revenue (Contract Liabilities, Current)($M)
11.743.204.802.5015.128.255.5716976.8103
Operating Lease Liabilities (Current)($M)
46.145.945.745.544.846.14641.942.141.741.741.5
Total Current Liabilities($M)
2,0631,5131,3501,4661,5561,3011,0761,1861,2211,055942968
Operating Lease Liabilities, Net of Current Portion($M)
203211218225223224230230236239238243
Other Noncurrent Liabilities($M)
10.69.207.607.609.8010.95.905358350320308
Total Liabilities($M)
4,3914,2054,0544,1774,6184,3154,0984,1734,1734,0134,0444,051
Accumulated Deficit($M)
-4,165-6,332-6,497-6,703-7,160-7,412-7,345-7,288-7,204-7,092-7,076-7,010
Total Stockholders' Equity (Deficit)($M)
3,6041,3541,07578958055542667.132.4-3.10-219-221
Common Shares Outstanding at Period End(M)
134134133132132131130129129128126126
Net Cash Provided by (Used in) Operating Activities($M)7
34132770.5218297130-120-94.743.7124-81.5-29.8
Capital Expenditures (Purchases of Property, Plant & Equipment)($M)
-69.8-34.7-21.8-23.3-12.1-14.3-9-9.10-4.20-8-13-15.3
Depreciation and Amortization($M)
14.513.913.613.513.813.914.414.2141513.513.5
Stock-Based Compensation Expense($M)
79.186.670.271.610811256.791.645.889.345.342
Net Cash Used in Investing Activities($M)
-312-364-25.5-37.2501-141114-52.9-30.233.9-67.6-241
Net Cash Provided by Financing Activities($M)
18.436.215.7-8.90-42077.746.13110313228.939.2
Cash Paid for Interest($M)
73.358.164.259.152.138.568.912.316.18.2030.95.40
Cash Paid for Income Taxes, Net of Refunds($M)
15.112.42.4012.71.30-1.9036.204.601.602

3 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY, CIK 0001178670) operates on a calendar fiscal year ending December 31 (latest completed fiscal year: FY2025 ended December 31, 2025; latest completed fiscal quarter: Q3 2026 / FY2026Q3 ended September 30, 2026). Alnylam manages and reports its business as a single global biopharmaceutical operating segment focused on RNA interference (RNAi) therapeutics.
  • Commercial operations center on two wholly-owned RNAi franchises and two partnered commercial RNAi medicines: (1) the TTR Amyloidosis Franchise ($1,226.4M in Q3 2026 / $2,487.5M in FY2025; +145% YoY at CER in Q3 2026), comprising subcutaneous AMVUTTRA (vutrisiran, $1,182.9M in Q3 2026 / $2,213.4M in FY2025 following March 2025 FDA approval in ATTR-CM) and intravenous ONPATTRO (patisiran, $43.5M in Q3 2026 / $274.1M in FY2025); (2) the Ultra-Rare Disease Franchise ($136.4M in Q3 2026 / $499.6M in FY2025; +12% YoY at CER in Q3 2026), comprising GIVLAARI (givosiran for AHP, $78.0M in Q3 2026 / $289.2M in FY2025) and OXLUMO (lumasiran for PH1, $58.5M in Q3 2026 / $210.4M in FY2025); and (3) Partnered Royalty & Collaboration Programs, led by Leqvio (inclisiran, $860M global net sales by Novartis in Q3 2026 / $3,063M in FY2025), Qfitlia (fitusiran, €31M global net sales by Sanofi in Q3 2026), Roche ($2.8B Zilebesiran alliance; $265.2M RPO at Q3 2026), and Regeneron ($232.9M RPO at Q3 2026).
  • Every brand is disaggregated across United States, Europe, and Rest of World (ex-U.S. & Europe) net product revenues alongside reported YoY % and Constant Exchange Rate (CER) YoY % growth rates, intra-year full-year guidance revisions, Gross-to-Net (GTN) rebate and chargeback reserve rollforwards ($419.5M ending reserve at Q3 2026), inventory by manufacturing stage ($113.0M total current + noncurrent inventory at Q3 2026), Blackstone royalty monetization and Level 3 development funding liabilities, functional R&D and SG&A expenses, Non-GAAP reconciliations, global workforce & ESG metrics, and standalone UK statutory accounts for wholly-owned subsidiary Alnylam UK Limited (#08871372, £84.60M turnover and 121 average employees in FY2025).
  • Under U.S. GAAP, Alnylam does not file parent-only standalone financial statements (Form 10-K omits Schedule I), so no Consolidated − Parent-only subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted metrics; bound disclosures such as 'over X patients' are excluded from table cells). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.

Không hiện vì thiếu các kỳ gần đây (8)

  • Commercial Patients on Therapy Worldwide (ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO) — Excluded because management disclosed patient counts exclusively as lower-bound approximations ('over X commercial patients worldwide', e.g., 'over 5,060' for AMVUTTRA/ONPATTRO and 'over 720' for GIVLAARI at Q3 2024) in quarterly earnings releases and discontinued quarterly patient-count reporting in FY2025–FY2026 following the ATTR-CM launch; exact point values in the SASB HC-BP-000.A table were only published for 3 years (FY2021–FY2023) and omitted from the 2024 and 2025 Corporate Responsibility Reports.
  • Compassionate Use / Early Access Program (EAP) Patient Counts — Excluded because annual Corporate Responsibility Reports disclose EAP patients only as lower-bound approximations ('960+ patients across 54 countries').
  • U.S. TTR Channel Inventory Days on Hand — Excluded because management only disclosed exact days-on-hand in two quarterly earnings calls (Q2 2026: ~11 days; Q3 2026: ~15 days), falling short of the 3-consecutive-quarter requirement.
  • U.S. Health System & Cardiology Payer Coverage Rates for AMVUTTRA in ATTR-CM — Excluded because management disclosed coverage milestones predominantly as qualitative or bound figures ('>90% of commercial lives', 'over 170 health systems') across 2025–2026 launch updates.
  • Clinical Pipeline Patient Enrollment Counts (SASB HC-BP-000.B / Clinical Trial Disclosures) — Excluded because exact trial enrollment totals across Phase 1/2/3 studies were only tabulated in the 2021–2023 Corporate Responsibility Reports and not reported for FY2024 or FY2025.
  • Initial Full-Year Financial Guidance Issued in January/February — Excluded as a standalone row because initial guidance is issued only once per year and initial sub-franchise guidance for TTR and Rare had only a single completed year; the complete quarterly guidance progression and year-end guidance history are presented in the Consolidated Commercial Execution & Full-Year Financial Guidance Progression group.
  • Legacy Partner Collaboration Sub-Series with Discontinued Activity (Sanofi Collaboration Revenue ended in FY2020; Novartis Reimbursed R&D ended in FY2020; Sanofi Reimbursed R&D ended in Q1 2021; Vir Biotechnology Reimbursed R&D ended in Q1 2022; Vir Biotechnology RPO ended in Q4 2022; Vir Biotechnology Deferred Revenue ended in Q4 2018) — Excluded due to lack of data in the 3 most recent quarters or 2 most recent fiscal years.
  • Strategic Collaborations, Partnered Royalty Streams & RPO Backlog (Key #4) › Net Revenues from Collaborations (Total) › Vir Biotechnology Collaboration Revenue (Annual) — Excluded due to insufficient recent consecutive periods.

Dữ liệu cập nhật 2026-11-10.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Alnylam Pharmaceuticals

See a number that looks wrong?